Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2015’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Interstitial Cystitis (Painful Bladder Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Interstitial Cystitis (Painful Bladder Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Interstitial Cystitis (Painful Bladder Syndrome) Overview 7
Therapeutics Development 8
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview 8
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis 9
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies 10
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes 11
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies 14
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes 15
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development 16
Afferent Pharmaceuticals, Inc. 16
Allergan, Inc. 17
Aquinox Pharmaceuticals Inc. 18
Kytogenics Pharmaceuticals, Inc. 19
Lipella Pharmaceuticals, Inc. 20
Qu Biologics Inc. 21
Urigen Pharmaceuticals, Inc. 22
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
(lidocaine + heparin) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AF-219 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AQX-1125 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GM-0111 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GM-1111 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lidocaine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LP-08 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
mesalamine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NEO-5024 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NEO-5937 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
onabotulinumtoxin A liposomal - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
QBECP-SSI - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Interstitial Cystitis (Painful Bladder Syndrome) - Recent Pipeline Updates 53
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects 58
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products 59
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones 60
Featured News & Press Releases 60
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 60
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 60
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND 61
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 62
Jul 23, 2013: Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 63
Apr 02, 2013: Taris Doses First Patient In Second Phase II Clinical Study Of LiRIS For Treatment Of Interstitial Cystitis 63
Nov 30, 2011: TARIS Initiates Phase II Clinical Study With LiRIS In Interstitial Cystitis Patients 64
Jun 30, 2011: Urigen Provides Development Update For URG101 64
Mar 09, 2011: TARIS Initiates Clinical Study In Interstitial Cystitis Patients 64
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2015 8
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H1 2015 16
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan, Inc., H1 2015 17
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 18
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H1 2015 19
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 20
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Qu Biologics Inc., H1 2015 21
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Assessment by Combination Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015 53
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2015 58
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2015 59